FDA Inspection 1175643 — Janssen Pharmaceuticals Inc.
The FDA completed an inspection of Janssen Pharmaceuticals Inc. on Jun 17, 2022 in Raritan, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 17, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Raritan, NJ (United States)